Table 1. Basic characteristics of the 23 SFTS patients who received favipiravir.

Categories	Subcategories	Overall (n = 23)	Groups		p-Value
			Fatal (n = 4)	Non-fatal (n = 19)
Gender	Male	14 (60.9%)	1 (25%)	13 (68.4%)	0.2601*
	Female	9 (39.1%)	3 (75%)	6 (31.6%)
Age (years)	Median (IQR)	71.0 (65, 81)	73.5 (63.5)	71.0 (65, 81)	0.9031†
	< 60	2 (8.7%)	0 (0%)	2 (10.5%)	0.7123*
	60–79	14 (60.9%)	2 (50%)	12 (63.2%)
	≥ 80	7 (30.4%)	2 (50%)	5 (26.3%)
Weight (kg) Ω	Median (IQR)	57.3 (50.0, 69.4)	47.5 (45.7, 58.7)	59.1 (50.4, 71.0)	0.1230†
BMI (kg/m2)Ω	Median (IQR)	22.2 (19.9, 25.1)	21.4 (20.4, 23.4)	23.1 (19.7, 26.0)	0.5429†
Time from onset to favipiravir initiation (days)	Median (IQR)	4 (3, 5)	4.5 (3 5.5)	4.0 (3, 5)	0.7730†
Underlying disease	Diabetes mellitus	4 (17.4%)	0 (0%)	4 (21.1%)	1.00*
	Cancer	1 (4.4%)	0 (0%)	1 (5.3%)	1.00*
	Hypertension	12 (52.2%)	0 (0%)	12 (63.2%)	0.0373*
	Hyperlipidaemia	5 (21.7%)	0 (0%)	5 (26.3%)	0.5392*

* Fisher’s exact test.

† Mann-Whitney U test.

Ω measured before initiation of favipiravir treatment.

n = number, IQR = interquartile range, BMI = body mass index.